LONDON, July 31, 2020 (GLOBE NEWSWIRE) — OKYO, the life sciences and biotechnology company, focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and
OKYO Pharma LTD (OKYO.L) Upcoming Presentation
Hemogenyx Pharma Plc (HEMO.L) New Corporate Video and Investor Webinar
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases.
Hemogenyx (HEMO.L) More Than A Covid-19 Gold Rush Play
I’ve written about Hemogenyx before, especially into the run up to and during the Great Covid-19 stocks rally of 2020.
Coronavirus (Covid-19) Vaccine Latest Update: Production of Oxford-AstraZeneca vaccine begins
Coronavirus (Covid-19) Vaccine Latest Update: AstraZeneca plans to roll out two billion doses of Covid-19 vaccine in September; human trials of Australian vaccine next month
4d Pharma (DDDD.L) pharma stock fighting COVID-19
Small-cap bounce back – pharma stocks fighting COVID-19
Scancell Holdings Plc (AIM:SCLP) Publication highlights potential of SCIB1 therapy
Scancell Holdings plc, (‘Scancell’ or the ‘Company’) the developer of novel immunotherapies for the treatment of cancer, is pleased to announce the publication of a peer-reviewed research paper in the
Shard Capital: Insights into the small pharmaceutical company sector (video)
Wealth Manager at Shard Capital Stockbrokers, Simon Niven, provides some insights into the small pharmaceutical company sector.
Synairgen Plc (AIM:SNG) Update on LOXL2 Programme & Pharmaxis Collaboration
Synairgen (LSE: SNG), the respiratory drug discovery and development company, today announces an update to its collaboration agreement with Pharmaxis and the Lysyl Oxidase type 2 (LOXL2) programme. Following the
ValiRx Plc (AIM:VAL) £1M placing at 1.25p
ValiRx Plc (AIM: VAL), a clinical stage biotechnology company, is pleased to announce it has conditionally raised £1.0 million of gross proceeds through the issue of 80,000,000 new ordinary shares
GlaxoSmithKline plc (LSE/NYSE:GSK) Trelegy Ellipta: positive opinion from CHMP Europe
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion
